Thank you for joining us in 2022!

Prostate Cancer Immunotherapy

November 12, 2022, 5:35 pm -
6:05 pm
Changing the outlook for metastatic prostate cancer

Session Description

As the second most common male cancer in the world, roughly 1.3 million people receive a prostate cancer diagnosis each year. In its early stages, prostate cancer is highly treatable, but when advanced, effective treatments are limited. That’s where cancer immunotherapy offers new hope. There are already two FDA-approved immunotherapies—a therapeutic cancer vaccine and a checkpoint inhibitor—and many more promising treatments in clinical trials. Join Dr. Lawrence Fong of the UCSF Helen Diller Family Comprehensive Cancer Center to discuss exciting scientific and clinical research. She’ll answer your questions about biomarkers and genomic sequencing, combination therapies, clinical trials, side effects, and more.


Lawrence Fong, MD

UCSF Helen Diller Family Comprehensive Cancer Center

Lawrence Fong, M.D. is the Efim Guzik Distinguished Professor in Cancer Biology in the Helen Diller Family Comprehensive Cancer Center at the University of California, San Francisco, where he leads the Cancer Immunotherapy Program. Dr. Fong also co-directs the Parker Institute of Cancer Immunotherapy at UCSF and co-leads the Cancer Immunity and Immunotherapy Program in the Cancer Center. He is a physician-scientist in the Department of Medicine, Division of Hematology/Oncology directing both a translational research program and an NIH-funded research lab. He is a leader in the field of cancer immunotherapy for having been involved in both pre-clinical and clinical studies of multiple immunotherapies including sipuleucel-T and immune checkpoint inhibitors that are now FDA-approved. This work includes first-in-human trials with dendritic cell vaccines, anti-CTLA-4, and adenosine antagonism. Dr. Fong’s laboratory research examines the mechanisms that underlie clinical response and resistance to immunotherapies. Throughout his career, he has innovated in the approaches to study cancer patients that include T cell receptor sequencing and high-dimensional single cell techniques. He has co-authored over 100 peer-reviewed research publications. He is an elected member of the Alpha Omega Alpha Honor Society and the American Society for Clinical Investigation. He is also an NIH Outstanding Investigator Award recipient. He has served as a standing member on multiple NIH study sections, the NCI Steering Committees for Genitourinary Cancer (GUSC), the NCI Investigational Drugs (IDSC)-Immunotherapy Task Force, the Department of Defense Prostate Cancer Research Program (PCRP) Vision Setting Committee, and the inaugural NCI Immuno-oncology Translation Network (IOTN) Steering Committee. He has also served on multiple journal editorial boards including the Journal of Clinical Oncology, Journal of Immunotherapy of Cancer, and Cancer Immunology Research.